文献速递甲状腺疾病

不可切除或转移性放射性碘难治性甲状腺癌的再分化治疗:国际甲状腺肿瘤学组声明

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-04-30

本文为国际甲状腺肿瘤学组声明,综述了再分化治疗在不可切除或转移性放射性碘难治性甲状腺癌中的应用。再分化即通过全身治疗恢复肿瘤对131I的摄取,短期使用MAPK抑制剂后给予高活度131I显示出有希望的结果,碘摄取恢复率为33%至95%,肿瘤缓解率为11%至80%,但试验间存在显著异质性,且缺乏随机研究。

要点

  • 短期使用MAPK抑制剂后给予高活度131I可恢复碘摄取并诱导肿瘤缓解。
  • 碘摄取恢复率为33%至95%,肿瘤缓解率为11%至80%。
  • 试验间在入选标准、再分化用药时长、放射性碘活度和剂量学使用方面存在显著差异。

核心结论

  • 再分化治疗在不可切除或转移性放射性碘难治性甲状腺癌中可行,短期MAPK抑制剂后给予高活度131I显示出有希望的结果。
  • 缺乏随机研究以明确再分化的有效性和适用性,需要长期研究来确定最有效的再分化方案。

研究设计与样本

  • 本文为国际甲状腺肿瘤学组声明,综述了前瞻性试验和病例报告的结果。

主要发现

  • 碘摄取恢复范围为33%至95%,肿瘤缓解率为11%至80%。
  • 再分化已在前瞻性试验中用于BRAF突变和RAS突变肿瘤患者,以及RET或NTRK融合患者。
  • 试验间在入选标准、再分化用药时长、放射性碘活度和剂量学使用方面存在显著差异。

局限性

  • 试验间在入选标准、再分化用药时长、放射性碘活度和剂量学使用方面存在显著差异。
  • 缺乏随机研究以明确再分化的有效性和适用性。
  • 需要长期研究来确定最有效的再分化方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with follicular cell-derived thyroid cancer that have distant metastases and no iodine uptake, redifferentiation-ie, the restoration of tumoural 131I uptake with systemic therapy-is now possible. The use of mitogen-activated protein kinase (MAPK) inhibitors for a short period of time before the administration of high activity 131I shows promising results with iodine uptake restoration and tumour response. Redifferentiation has been used in patients with BRAF-mutated and RAS-mutated tumours in prospective trials and in the case of patients with RET or NTRK fusions. The iodine uptake restoration ranges from 33% to 95%, and tumour response rates from 11% to 80%. There is substantial variability between trials with regards to inclusion criteria, duration of redifferentiation drug therapy, activity of radioactive iodine, and use of dosimetry. Randomised studies are missing to clearly establish the effectiveness and applicability of redifferentiation. Thus, long-term studies are needed to establish the most effective redifferentiation protocols. The objectives of this Review are to: (1) provide a comprehensive review of the available results from prospective trials and case reports, including results regarding the restoration of radioiodine uptake and treatment efficacy (morphological and biological); (2) describe the differences in redifferentiation trial design between studies and discuss their potential impact on treatment efficacy; (3) describe the implications and limitations of dosimetry; and (4) outline the key questions to be addressed in future redifferentiation trials.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Leboulleux S, Boucai L, Busaidy N, et al. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025. PMID: 40318680. doi:10.1016/S2213-8587(25)00064-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。